Recurrent Glomerulonephritis After Renal Transplantation
Recurrent Primary Glomerulonephritis After Renal Transplantation: Effects on Renal Allografts and Transplant Recipients
1 other identifier
observational
360
1 country
2
Brief Summary
Glomerulonephritis (GN) is the leading cause of end-stage renal disease in 30% to 50% of patients who receive a renal transplant. The exact prevalence of either recurrent or de novo GN is unknown since a considerable number of patients never undergo allograft biopsy, leaving GN underdiagnosed. The aim of this study is to evaluate the effects of recurrent GN on the prevalence, risk factors, clinicopathological features, and outcome of renal transplant recipients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2015
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 25, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedFirst Posted
Study publicly available on registry
March 7, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedApril 5, 2016
April 1, 2016
1 year
February 25, 2016
April 3, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Allograft survival
1 - 5 years
Secondary Outcomes (1)
Allograft rejection
1 - 5 years
Study Arms (3)
Recurrent GN
Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
Non-recurrent GN
Renal transplant recipients with non-recurrent primary glomerulonephritis.
Non-GN
Renal transplant recipients with etiologies other than primary glomerulonephritis.
Eligibility Criteria
Renal transplant recipients
You may qualify if:
- Patients who underwent a renal transplantation because of an end-stage renal disease caused by primary glomerulonephritis and have biopsy-proven recurrent primary glomerulonephritis (Recurrent GN group)
- Patients who underwent a renal transplantation because of an end-stage renal disease caused by primary glomerulonephritis and have no signs of recurrence (Non-recurrent GN group)
- Patients who underwent a renal transplantation because of an end-stage renal disease linked to an etiology other than primary glomerulonephritis (Non-GN group)
You may not qualify if:
- Patients who are unwilling or unable to consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Istanbul, 34093, Turkey (Türkiye)
Division of Nephrology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine
Istanbul, Turkey (Türkiye)
Related Publications (1)
Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002 Jul 11;347(2):103-9. doi: 10.1056/NEJMoa013036.
PMID: 12110738BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yasar Caliskan, MD
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Medicine
Study Record Dates
First Submitted
February 25, 2016
First Posted
March 7, 2016
Study Start
March 1, 2015
Primary Completion
March 1, 2016
Study Completion
April 1, 2016
Last Updated
April 5, 2016
Record last verified: 2016-04